The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts

Experts in Chronic Myeloid Leukemia

Research output: Contribution to journalArticle

399 Citations (Scopus)

Abstract

As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

Original languageEnglish (US)
Pages (from-to)4439-4442
Number of pages4
JournalBlood
Volume121
Issue number22
DOIs
StatePublished - May 30 2013

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Health Policy
Health care
Pharmaceutical Preparations
Delivery of Health Care
Neoplasms
Long-Term Care
Protein-Tyrosine Kinases
Patient Care
Acoustic waves
Costs and Cost Analysis
Costs
Therapeutics

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs : From the perspective of a large group of CML experts. / Experts in Chronic Myeloid Leukemia.

In: Blood, Vol. 121, No. 22, 30.05.2013, p. 4439-4442.

Research output: Contribution to journalArticle

@article{1f60ea9e451f4817b72407c64f350afb,
title = "The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts",
abstract = "As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.",
author = "{Experts in Chronic Myeloid Leukemia} and Camille Abboud and Ellin Berman and Adam Cohen and Jorge Cortes and Daniel DeAngelo and Michael Deininger and Steven Devine and Brian Druker and Amir Fathi and Elias Jabbour and Madan Jagasia and Hagop Kantarjian and Jean Khoury and Pierre Laneuville and Richard Larson and Jeffrey Lipton and Moore, {Joseph O.} and Tariq Mughal and Susan O'Brien and Javier Pinilla-Ibarz and Alfonso Quintas-Cardama and Jerald Radich and Vishnu Reddy and Charles Schiffer and Neil Shah and Paul Shami and Silver, {Richard T.} and David Snyder and Richard Stone and Moshe Talpaz and Ayalew Tefferi and {Van Etten}, {Richard A.} and Meir Wetzler and Elisabetta Abruzzese and Jane Apperley and Massimo Breccia and Jenny Byrne and Francisco Cervantes and Ekaterina Chelysheva and Clark, {R. E.} and {De Lavallade}, Hugues and Iryna Dyagil and Carlo Gambacorti-Passerini and John Goldman and Ibrahim Haznedaroglu and Henrik Hjorth-Hansen and Tessa Holyoake and Brian Huntly and {Le Coutre}, Philipp and Elza Lomaia",
year = "2013",
month = "5",
day = "30",
doi = "10.1182/blood-2013-03-490003",
language = "English (US)",
volume = "121",
pages = "4439--4442",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs

T2 - From the perspective of a large group of CML experts

AU - Experts in Chronic Myeloid Leukemia

AU - Abboud, Camille

AU - Berman, Ellin

AU - Cohen, Adam

AU - Cortes, Jorge

AU - DeAngelo, Daniel

AU - Deininger, Michael

AU - Devine, Steven

AU - Druker, Brian

AU - Fathi, Amir

AU - Jabbour, Elias

AU - Jagasia, Madan

AU - Kantarjian, Hagop

AU - Khoury, Jean

AU - Laneuville, Pierre

AU - Larson, Richard

AU - Lipton, Jeffrey

AU - Moore, Joseph O.

AU - Mughal, Tariq

AU - O'Brien, Susan

AU - Pinilla-Ibarz, Javier

AU - Quintas-Cardama, Alfonso

AU - Radich, Jerald

AU - Reddy, Vishnu

AU - Schiffer, Charles

AU - Shah, Neil

AU - Shami, Paul

AU - Silver, Richard T.

AU - Snyder, David

AU - Stone, Richard

AU - Talpaz, Moshe

AU - Tefferi, Ayalew

AU - Van Etten, Richard A.

AU - Wetzler, Meir

AU - Abruzzese, Elisabetta

AU - Apperley, Jane

AU - Breccia, Massimo

AU - Byrne, Jenny

AU - Cervantes, Francisco

AU - Chelysheva, Ekaterina

AU - Clark, R. E.

AU - De Lavallade, Hugues

AU - Dyagil, Iryna

AU - Gambacorti-Passerini, Carlo

AU - Goldman, John

AU - Haznedaroglu, Ibrahim

AU - Hjorth-Hansen, Henrik

AU - Holyoake, Tessa

AU - Huntly, Brian

AU - Le Coutre, Philipp

AU - Lomaia, Elza

PY - 2013/5/30

Y1 - 2013/5/30

N2 - As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

AB - As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

UR - http://www.scopus.com/inward/record.url?scp=84880790088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880790088&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-03-490003

DO - 10.1182/blood-2013-03-490003

M3 - Article

C2 - 23620577

AN - SCOPUS:84880790088

VL - 121

SP - 4439

EP - 4442

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -